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BACKGROUND: Three lung cancer (LC) models have recently been constructed to predict an individual’s absolute risk of LC within a
defined period. Given their potential application in prevention strategies, a comparison of their accuracy in an independent population
is important.
METHODS: We used data for 3197 patients with LC and 1703 cancer-free controls recruited to an ongoing case–control study at the
Harvard School of Public Health and Massachusetts General Hospital. We estimated the 5-year LC risk for each risk model and
compared the discriminatory power, accuracy, and clinical utility of these models.
RESULTS: Overall, the Liverpool Lung Project (LLP) and Spitz models had comparable discriminatory power (0.69), whereas the
Bach model had significantly lower power (0.66; P¼0.02). Positive predictive values were highest with the Spitz models, whereas
negative predictive values were highest with the LLP model. The Spitz and Bach models had lower sensitivity but better specificity
than did the LLP model.
CONCLUSION: We observed modest differences in discriminatory power among the three LC risk models, but discriminatory powers
were moderate at best, highlighting the difficulty in developing effective risk models.
British Journal of Cancer (2010) 103, 423–429. doi:10.1038/sj.bjc.6605759 www.bjcancer.com
Published online 29 June 2010
& 2010 Cancer Research UK
Keywords: lung cancer; risk model; 5-year lung cancer risk; relative risks; discriminatory power
                                                                                                               
Worldwide, an estimated 1.35 million new lung cancer (LC) cases
and 1.18 million LC-related deaths occur every year (Parkin et al,
2005). It has been suggested that B70% of all LCs could be
prevented by reducing the prevalence of major risk factors,
particularly smoking (Danaei et al, 2005). Given that LC risk
differs greatly among smokers, the ability to estimate an
individual’s absolute risk could be used to guide preventive
interventions. In particular, absolute risk scores could be used
both to motivate individuals to reduce their LC risk through
behaviour and lifestyle modifications and to refine selection of
participants for LC screening trials on the basis of maximising
benefit (Vickers et al, 2006; Duffy et al, 2009). Other cancers that
have well-known risk-prediction models include breast (Gail et al,
1989; Tyrer et al, 2004; Tice et al, 2005), colorectal (Imperiale et al,
2000; Selvachandran et al, 2002), melanoma (Cho et al, 2005;
Fears et al, 2006), ovarian (Hartge et al, 1994), and bladder cancers
(Wu et al, 2007).
Within the last decade, three models to estimate an individual’s
absolute LC risk were developed: the Bach (Bach et al, 2003), Spitz
(Spitz et al, 2007), and the Liverpool Lung Project (LLP) models
(Cassidy et al, 2008). All the three models share risk factors
(such as smoking duration and occupational exposure to
asbestos); however, differences arise, with the inclusion of lung-
related comorbidities or family history information. These models
have not previously been compared in an independent data set in
terms of discriminatory power, accuracy, and clinical utility. Such
a comparison, to evaluate whether these published risk models have
similar discriminatory power for a given population of individuals, is
important, given the potential application of risk-prediction models
to strategies for primary and secondary preventions.
In this study, we used each of these models to estimate 5-year
absolute LC risks for an independent population of LC patients
and healthy controls. We compared the discriminatory power of
these three models by calculating the area under the curve (AUC)
of the receiver operator characteristic (ROC) curve for each 5-year
absolute risk estimate. We evaluated the accuracy and compared
the positive predictive value (PPV; the probability of accurately
categorising an affected participant) and the negative predictive
value (NPV; the probability of accurately categorising an
unaffected participant) among the three risk models; we also
evaluated the clinical utility of each.
MATERIALS AND METHODS
A total of 4900 LC patients and controls were accrued for this
study, 3197 were treated in the Thoracic Surgery, Thoracic
Oncology, or Pulmonary Units at the Massachusetts General
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yHospital (MGH) (Boston, MA, USA). Starting in 1992, enrolment
was initially restricted to patients with operable LC; however, case
definition was expanded in August 1996 to include inoperable LC
to reflect the full spectrum of LC patients. Lung cancer diagnosis
was histologically confirmed by a lung pathologist. Controls
(N¼1703) were LC-free individuals initially accrued from among
family members or friends of cases, but accrual was subsequently
expanded to include friends and family (not blood related to study
cases) of individuals being treated at the MGH for non-LC diseases
(Xu et al, 1996; Garcia-Closas et al, 1997; Wang et al, 2001).
Inclusion of risk factors in the three LC risk models is
summarised in Table 1. Smokers were defined as those who had
smoked 4400 cigarettes in their lifetime; former smokers were
those who had quit smoking at least 1 year before the cancer
diagnosis (patients) or the interview (controls). Smoking duration
was determined by subtracting the age at which the participant had
started smoking from either the age at which the participant had
quit smoking (former smokers) or the participant’s current age
(current smokers). Pack-years were calculated by multiplying the
smoking duration (in years) by the number of cigarettes smoked
per day and then dividing by 20. Time of smoking cessation
for former smokers was determined by subtracting the age at
which the participant had quit smoking from the participant’s
current age.
Participants were classified as positive for asbestos exposure if
they had been directly exposed for at least 8h per week for a year
or if they were employed in an asbestos-related industry
(according to the Standard Industrial Classification Manual
(1972) and/or the Dictionary of Occupational Titles (1991)).
Exposure to wood dusts (including sawdust or sanding dust) for
at least 8h per week for a year was self-reported, or for a family
history of any cancer if at least two first-degree relatives had
cancer. Participants were classified as positive for a family history
of any smoking-related cancer if at least one first-degree relative
had had cancer at some point in his or her life. Participants were
also classified by self-reported physician-diagnosed emphysema or
hay fever at any time before study entry (Spitz) or by physician-
diagnosed pneumonia at least 2 years before entry (LLP).
Any study participant with missing data for any of the risk factors
for any model was excluded from analysis. As all three models were
developed using data obtained from White participants, we only
included individuals who self-reported being non-Hispanic White.
For the comparison of discriminatory power between the LLP and
Bach models and the Spitz and Bach models only ever smokers
(total of 1066 LC and 677 controls) were used as the Bach model was
developed only for ever smokers (Bach et al, 2003). In the comparison
between the LLP and Spitz models, never, former, and current
smokers were included (total of 1121 LC and 1024 controls).
The institutional review boards at the M. D. Anderson Cancer
Center, MGH, and the Harvard School of Public Health approved
this study.
We calculated the 5-year absolute risk of LC for the three
models, using MatLab software (The MathWorks Inc., Natick, MA,
USA). For the Bach model, they were obtained by running 1-year
incidence and mortality models recursively five times, with each
individual contributing to the predicted risk for 5 years. For the
Spitz and LLP models, they were estimated by combining the risk
of cancer from the relative risk model with age- and gender-
specific LC incidence rates.
Details regarding the exact calculation of risk for each model
were given in the original paper (Bach et al, 2003; Spitz et al, 2007;
Cassidy et al, 2008). With the LLP model, the a-value used
to calculate the 5-year absolute risk was adjusted for the US LC
incidence rate (Appendix Table A1). For each participant, we had
three estimates of absolute risk for LC (one from each model). For
each model, we used NCSS statistical software (NCSS, Kaysville,
UT, USA) to calculate the specificity and sensitivity required to
construct ROC curves and estimate AUC (binomial method) and
the 95% confidence interval (95% CI) for each of the three models.
We also calculated the AUC after stratification of participants by
sex and age (o50 vs X50 years). We then conducted pairwise
comparisons of the AUCs of the three models using the method
described in the NCSS package (Hanley and McNeil, 1983), the test
statistic for comparing two ROC curves being given by
z ¼
AUC1   AUC2 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s:e:2
1 þ s:e:2
2   2rs:e:1s:e:2
p ;
where AUCi is the area under the ROC curve from the ith model
(i¼1,2), s.e.i the s.e. of AUCi, and r the correlation between AUC1
and AUC2 (Tyrer et al, 2004). The test statistic z follows a standard
normal distribution; and values of z4z1 a are interpreted as
evidence that AUC1 is significantly greater than AUC2 for the given
a-level.
From these risk factors, a relative risk was calculated and
combined with age- and gender-specific incidence rates from x
(SEER) (SEER, 2005), and all-cause mortality (excluding LC) rates
from CDC (Centers for Disease Control) to estimate the
absolute risk of LC (National Center for Health Statistics, 2003)
(Appendix Table A2). As most of the absolute risk calculations
Table 1 Lifestyle variables used in the Bach, LLP, and Spitz models
Variables Bach LLP Spitz
Cigarettes smoked per day Yes No No
Smoking duration Yes Yes No
Pack-years No No Yes
Cessation duration Yes No No
Age stopped smoking No No Yes
Age Yes Used for LC incidence rate Used for LC incidence rate and LC-free mortality rate
Sex Yes Used for LC incidence rate Used for LC-specific incidence rate and LC-free mortality rate
Family history No Yes Yes
Asbestos exposure Yes Yes Yes
Wood dust exposure No No Yes
Emphysema No No Yes
Hay fever No No Yes
Pneumonia No Yes No
Malignant tumour No Yes No
LC incidence rate Yes (1-year recursed 5 times) Yes (modelled for five years) Yes (SEER rate)
LC-free mortality rate Yes (1-year recursed 5 times) No Yes (NCHS rate)
Abbreviations: LLP¼Liverpool Lung Project; LC¼lung cancer; SEER¼Surveillance and End Results; NCHS¼National Center for Health Statistics.
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Bonferroni correction was taken into account to adjust for any
multiple comparisons issues.
We calculated the PPV and NPV for each of the models
(Spitz, Bach, and LLP) separately for all participants and then
stratified them by smoking status (former and current). We
conducted pairwise comparisons (Spitz vs LLP, Spitz vs Bach, and
Bach vs LLP) of the PPV and NPV to test differences of these two
statistics among the three models using the normal approximation
to the test of two proportions. As with the absolute risk results, the
Bonferroni correction was used for both the PPV and the NPV to
adjust for multiple testing. Clinical utility of the models was
evaluated using scaled rectangle diagrams as implemented in the
Search Partition Analysis (SPAN, Auckland, New Zealand)
program (Marshall, 2001, 2005, 2009). Scaled rectangle diagrams
display the joint occurrence of attributes (namely risk for disease)
for a risk model and true disease status and provide a visual
presentation of how well a model discriminates. With these
diagrams, the white rectangle represents all individuals, the green
rectangle represents all cases, and the blue, purple, and red
rectangles represent individuals with three increasing levels of LC
risk (2.5, 5, and 7.5%, respectively). Models with high clinical
utility will have the vast majority of their cases, have higher levels
of risk, and have fewer controls with those individuals at the higher
LC absolute risk.
RESULTS
The epidemiological and demographic data for the validation set
of 1066 LC patients and 677 controls are presented in Table 2.
Patients (mean age, 64.8 years) were older than controls (mean
age, 61.1 years; Po0.001). The majority of patients (58%) and
controls (52%) were male. There was a higher percentage of
former smokers among controls (74.2%) than among patients
(56.2%; Po0.001). Lung cancer patients who were current smokers
smoked significantly more cigarettes per day (mean, 29.9), and had
smoked for longer periods (mean, 43.8 years) than did controls
(mean cigarettes smoked per day: 21.1, Po0.001; smoking
duration: 38.5 years, Po0.001). Similarly, patients who were
former smokers had smoked significantly more cigarettes per day
(mean, 30.6) and had smoked for longer periods (mean, 34.8 years)
than did controls (mean cigarettes smoked per day: 22.9, Po0.001;
smoking duration: 24.2 years, Po0.001). Lung cancer patient pack-
years were over 24units higher in both current and former
smokers than in controls, and these differences were highly
significant in both smoking groups (Po0.001). Controls reported
longer quitting durations (mean, 19.8 years) than did patients
(mean, 14.1 years; Po0.001). Former smokers more after reported
a family history of any cancer (34.4%) and smoking-related
cancers (30.6%) than did controls (any cancer: 27.9%, P¼0.023;
smoking-related cancers: 22.9%, P¼0.005); and current smokers
reported a significantly higher percentage of smoking-related
cancers (30.4%) than did controls (22.3%, P¼0.049).
The discriminatory power for the three models, overall and
stratified by smoking, age, and sex, are summarised in Table 3, the
AUCs being 0.69 for the Spitz (95% CI¼0.66–0.71) and LLP
(95% CI¼0.67–0.71) models and 0.66 (95% CI¼0.64–0.69) for
the Bach model. The differences in discriminatory power between
the LLP and Bach models were significant (P¼0.023), and the
differences between the Spitz and Bach models reached borderline
significance (P¼0.072). Among former smokers, the discrimina-
tory power was 0.70 (95% CI¼0.67–0.73) for the Spitz and
LLP models and 0.65 (95% CI¼0.62–0.68) for the Bach model.
Among current smokers, the discriminatory power was 0.68 (95%
CI¼0.64–0.72) for the Spitz model, 0.65 (95% CI¼0.60–0.69) for
the Bach model, and 0.66 (95% CI¼0.62–0.70) for the LLP model.
Among former smokers, the Bach model was outperformed by
both the LLP (P¼0.002) and the Spitz (P¼0.008) models, whereas
among current smokers, only the Spitz model significantly
outperformed the Bach model (P¼0.024). When incorporating
never smokers for testing discriminatory power, the LLP model
Table 2 Demographic characteristics of study population used to compare discriminatory power and accuracy of the Spitz, Bach, and LLP risk models
Cases (N¼1066) Controls (N¼677) P-value
Age (years): mean±s.e. 64.8±9.7 61.1±9.8 o0.001
Smoking status: no. (%)
Current 467 (43.8) 175 (25.8) o0.001
Former 599 (56.2) 502 (74.2)
Current smokers
Smoking duration (years): mean±s.e. 43.9±10.3 38.5±10.5 o0.001
Cigarettes per day: mean±s.e. 29.9±14.8 21.1±11.9 o0.001
Pack-years: mean±s.e. 65.7±37.1 41.2±26.3 o0.001
Family history of cancer (no. % of family members)
o2 320 (68.5) 130 (74.3) 0.176
X2 147 (31.5) 45 (25.7)
Family history of a smoking-related cancer (no. % of family members)
0 325 (69.6) 136 (77.7) 0.049
X1 142 (30.4) 39 (22.3)
Former smokers
Smoking duration (years): mean±s.e. 34.8±12.3 24.2±12.8 o0.001
Cigarettes per day: mean±s.e. 30.6±16.4 22.9±16.0 o0.001
Pack-years: mean±s.e. 55.3±36.3 30.6±28.5 o0.001
Years since smoking cessation: mean±s.e. 14.1±10.9 19.8±12.1 o0.001
Family history of cancer (no. % of family members)
o2 393 (65.6) 362 (72.1) 0.023
X2 206 (34.4) 140 (27.9)
Family history of a smoking-related cancer (no. % of family members)
0 416 (69.4) 387 (77.1) 0.005
X1 183 (30.6) 115 (22.9)
Abbreviation: LLP¼Liverpool Lung Project.
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(AUC¼0.68, 95% CI¼0.66–0.71) significantly (P¼0.001).
We also tested the discriminatory power of all models when
participants were stratified by age and sex (Table 3) and for
women over the age of 50 years, observed significant differences in
discriminatory power between the Spitz and Bach models, and the
LLP and Bach models.
Table 4 summarises the NPV and PPV results for each. Overall,
the three models had reasonable PPV levels (all 470%); the Spitz
model had a significantly higher PPV (88.2%) than those of the
LLP (75.9%; Po0.001) and the Bach (80.9%; P¼0.009) models.
Among former smokers, the Spitz model had significantly higher
PPV (85.5%) than did the LLP model (72.6%; Po0.001) but not
significantly higher PPV than the Bach model (83.6%; P¼0.851).
However, among current smokers, the Spitz model had higher PPV
(91.9%) than did the Bach (80.4%; P¼0.002) and the LLP (80.9%;
Po0.001) models. The overall NPV for each of the three models
were lower than the PPV (range¼45.0–56.0%), with the LLP
model having a substantially better probability of accurately
categorising an unaffected participant. The LLP model was also
significantly better for the NPV among former smokers, but both
the Spitz and Bach models were competitive with the LLP model in
calculating the NPV among current smokers.
To demonstrate the clinical utility of each model, Table 5
presents the percentages of patients and controls with LC risk
estimates of 42.5, 5, and 7.5% as determined by each model.
Using a cutoff of 42.5% risk as an example, the percentages of LC
patients that were correctly identified by the Spitz, Bach, and LLP
risk models were 26.6, 30.2, and 66.7%, respectively. The
percentages of controls with 42.5% risk that were incorrectly
identified as LC patients by the Spitz, Bach, and LLP risk models
were 5.6, 11.2, and 33.4%, respectively. For all three models, setting
a higher risk cutoff resulted in a lower proportion of controls being
incorrectly identified as LC patients and a lower proportion of LC
patients being correctly identified. This is evident in the scaled
rectangle diagrams for the Spitz, Bach, and LLP risk models at
cutoffs of 42.5, 5, and 7.5% absolute risk, respectively (Figure 1).
Table 3 Discriminatory power for the Spitz, Bach, and LLP risk models, overall and stratified by smoking, age, and sex
P-value
Model
Area under
the curve
Asymptotic 95%
confidence interval (1) (2)
Overall Spitz 0.69 0.66–0.71
Bach 0.66 0.64–0.69 0.07
LLP 0.69 0.67–0.71 0.61 0.02
Current smokers Spitz 0.68 0.64–0.72
Bach 0.65 0.60–0.69 0.02
LLP 0.66 0.62–0.70 0.23 0.45
Former smokers Spitz 0.70 0.67–0.73
Bach 0.65 0.62–0.68 0.01
LLP 0.70 0.67–0.73 0.71 o0.01
Age group (years) Sex
o50 Women Spitz 0.59 0.46–0.69
Bach 0.62 0.49–0.72 0.63
LLP 0.62 0.49–0.72 0.64 0.99
o50 Men Spitz 0.70 0.58–0.78
Bach 0.68 0.56–0.77 0.66
LLP 0.67 0.56–0.76 0.65 0.96
X50 Women Spitz 0.70 0.66–0.73
Bach 0.65 0.61–0.69 0.05
LLP 0.69 0.66–0.73 0.86 0.04
X50 Men Spitz 0.68 0.64–0.71
Bach 0.67 0.63–0.70 0.63
LLP 0.70 0.67–0.74 0.13 0.09
Abbreviation: LLP¼Liverpool Lung Project. (1) P-value comparisons for the Spitz and Bach models and the Spitz and LLP models. (2) P-value comparisons for the Bach and LLP
models. Bold values represent results still significant to the 5% level after using the Bonferroni method for multiple corrections.
Table 4 Positive predictive and negative predictive values (PPV and
NPV, respectively) examination using a predictive cutoff of 2.5%
P-value P-value
Smoking status Model PPV (1) (2) NPV (1) (2)
All Spitz 0.882 0.450
Bach 0.809 0.009 0.447 0.911
LLP 0.759 o0.001 0.049 0.560 o0.001 o0.001
Former Spitz 0.855 0.520
Bach 0.836 0.851 0.526 0.832
LLP 0.726 o0.001 0.058 0.649 o0.001 o0.001
Current Spitz 0.919 0.323
Bach 0.804 0.002 0.354 0.418
LLP 0.809 o0.001 0.943 0.384 0.110 0.507
Abbreviation: LLP¼Liverpool Lung Project. (1) Comparison of the Spitz and Bach
and the Spitz and LLP models. (2) Comparison of Bach and LLP values. Bold values
represent results still significant to the 5% level after using the Bonferroni method for
multiple corrections.
Table 5 Clinical utility of the Spitz, Bach, and LLP risk models estimated
as percentage of participants with risk estimates 42.5, 5.0, and 7.5%
Model RiskX2.5% RiskX5.0% RiskX7.5%
Percentage (%) of cases
Spitz 26.6 6.8 2.2
Bach 30.2 15.5 6.4
LLP 66.7 45.5 31.2
Percentage (%) of controls
Spitz 5.6 0.7 0.0
Bach 11.2 2.4 1.2
LLP 33.4 15.1 7.7
Abbreviation: LLP¼Liverpool Lung Project.
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patients who were not identified by the Spitz and Bach models, but
it also incorrectly identified 139 controls as LC patients. Although
the Spitz and Bach models identified fewer LC patients (17 and 15,
respectively), significantly fewer controls were incorrectly identi-
fied as patients (5 and 8, respectively) compared with the LLP
model. Using the 47.5% risk cutoff, the Spitz model had 100%
specificity, but its sensitivity was impractically low (2.2%). At this
level of risk, for every four LC patients correctly identified by the
LLP model, one control was incorrectly identified as a LC patient,
wherein as the equivalent patient-to-control ratio for the Bach
model was 5 to 1.
DISCUSSION
The purpose of this analysis was to compare the discriminatory
power and accuracy of three LC risk-prediction models using an
external set of LC cases and controls. We observed that the Spitz
and LLP models had similar abilities to discriminate between
former and current smoking cases and controls and that each of
these models outperformed the Bach model. The Spitz and LLP
models incorporated population-based incident LC rates, which
could account for their better discriminatory power than that
of the Bach model. For every 5-year age group from 20 to 89 years,
we incorporated the SEER rates for the incidence of LC
and the mortality rates from all causes other than LC (Appendix
Table A1). In terms of model accuracy, the Spitz model had higher
PPV than did the LLP and Bach models among both types of ever
smokers, but the LLP model outperformed both the Spitz and Bach
models in terms of the NPV. In terms of clinical utility, the Spitz
model had the lowest false-positive rate for risk estimates 42.5%,
whereas the LLP model had the highest false-positive rate. At all
levels of risk, the LLP model correctly identified a higher
proportion of LC patients than did the other models did but
also incorrectly identified a higher proportion of controls as LC
patients.
Each model included some form of tobacco exposure. In the
Bach model, the variables – duration of smoking (in years) and
number of cigarettes smoked per day – are included for both
former and current smokers. In the Spitz model (controls matched
to cases on smoking status), the duration of smoking and numbers
of cigarettes smoked per day are combined into pack-years for
current smokers only and into age at smoking cessation for former
smokers. The Bach and LLP models do not include a smoking
cessation variable. The Bach model included smokers aged 50–75
years who are/were heavy smokers (10–60 cigarettes per day for
25–60 years) and who had quit no more than 20 years previously
(Bach et al, 2003).
In terms of clinical utility, the Spitz and Bach models performed
reasonably well in identifying LC patients at defined levels of risk
while limiting the number of false-positive results. However, the
LLP model was much better at identifying individuals with LC but
also had a much higher false-positive rate than the Spitz and Bach
models had. This could be attributed to the importance of smoking
in the LLP model. The Spitz model’s relatively low recognition of
cancer patients with a 42.5% absolute LC risk could be caused by
smoking being a matching variable in the model rather than a risk
factor. The overall high (475%) PPVs for the three models
indicate that they can identify high-risk individuals; however, the
overall relatively low NPVs (between 45 and 56%) indicate that
many low-risk individuals would be identified as well. The scaled
rectangle diagrams illustrate more clearly the modest discrimina-
tory performances of the Spitz, Bach, and LLP models and provide
a sobering message about LC risk prediction. To substantially
improve LC risk discriminatory power for individual patients, we
need to identify a risk factor (other than smoking habits) that has a
different distribution in LC patients from those who will not
develop it; to date, there is no evidence for such a factor. High
expectations have been pinned on genome-wide association
studies, which have successfully identified hundreds of common
genetic variants that are strongly associated with the risk of more
than 40 diseases, including LC (Kraft and Hunter, 2009). However,
a strong association does not necessarily guarantee good
classification or discriminatory ability (Jakobsdottir et al, 2009).
It was recently shown that on average, 80 common variants with
odds ratios of 1.25 each were required to develop a model useful
for the identification of high-risk individuals (AUC40.80) for
genetic profiling studies (Janssens et al, 2006).
Our study had some limitations. The most important limitation
is that the study design is a case–control study, which could lead
to some recall bias with the self-reported variables, such as
smoking and environmental tobacco smoke exposure (Asomaning
et al, 2008). However, in this study, controls were recruited from
family and friends of those being treated for LC at the MGH, so
that exposures for the self-reported variables would be similar or
non-differential, among cases and controls, which would limit
recall bias (Miller et al, 2003). With non-differential biases, AUC
results will regress to the null, so it is possible that the AUC results
are conservative instead of overstated (Greenland and Lash, 2008).
Other minor limitations include that the risk-prediction models
compared in our study were developed in Caucasian populations,
so the validation was also restricted to Caucasians, and thus, the
models may not be applicable to other racial or ethnic groups.
Spitz model
AB C
Bach Model LLP Model
Figure 1 Clinical utility of the Spitz, Bach, and LLP models. Scaled rectangle diagrams for (A) the Spitz, (B) Bach, and (C) LLP risk models at defined levels
of lung cancer risk. For each colour of the diagram: white equals all controls with o2.5% risk, and green equals all cases with o2.5% risk. Blue represents
all individuals with at least 2.5% risk, but o5% risk. Purple represents all individuals with at least 5.0% risk, but o7.5% risk. Red represents all individuals with
at least 7.5% risk.
Diagnostic accuracy of three LC models
AM D’Amelio et al
427
British Journal of Cancer (2010) 103(3), 423–429 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yIn addition, for most of the analysis, we only included ever-smoker
cases and controls in our analysis, and thus, the enormous
contribution of smoking to LC risk was effectively underestimated.
The ultimate test of a model’s application is its accurate prediction
of risk in an independent data set. However, direct comparison of
risk models is complicated by the fact that few studies have
population samples that are large enough and diverse enough in
age and risk factor backgrounds (Cassidy et al, 2007). Thus, to
avoid possible information bias, it was imperative for our analysis
to select only patients and controls from those who had complete
information relating to risk-model covariates.
Despite these limitations, our analyses showed that LC risk-
prediction models performed reasonably well when compared with
each other in an independent validation set. All models include
biologically plausible and well-established risk factors that have
been shown to be significant in previous studies. One possible
caveat is that the discriminatory values do not exceed 0.75, a value
that has been suggested for the screening of individuals with an
increased risk of disease (Janssens et al, 2007). This relatively low
discriminatory value suggests that there is much work yet to be
accomplished in LC risk prediction, especially compared with
other cancer risk models such as colorectal cancer, which has a
concordance statistic between 0.84 and 0.86 (Selvachandran et al,
2002). However, the discriminatory power results for LC compare
favourably with those models for breast cancer (0.58–0.68) and
melanoma (0.62) (Rockhill et al, 2003; Cho et al, 2005; Tice et al,
2005). Future improvements in the discriminatory ability of LC
risk models may be possible by the incorporation of biomarkers
related to LC risk, top hits from genome-wide association studies,
rare variants, or a combination of these with lifestyle and
environmental risk factors. Improved LC risk models offer an
enormous potential benefit to guide the physician’s and the
patient’s perception of individual risk of disease.
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Appendix
Table A1 Estimated a-values for determination of 5-year absolute risk for the LLP risk model (Cassidy et al, 2008; SEER, 2005)
Male Female
Age group (years) Incidence rate
a a-value Incidence rate
a a-value
40–44 10.78  9.42 11.03  9.29
45–49 25.49  8.56 23.19  8.54
50–54 56.60  7.76 45.51  7.86
55–59 116.58  7.02 93.93  7.13
60–64 221.18  6.37 164.90  6.56
65–69 346.77  5.91 246.85  6.15
70–74 478.10  5.57 318.69  5.88
75–79 564.36  5.37 344.67  5.79
80–84 532.36  5.43 308.28  5.91
Abbreviation: SEER¼Surveillance and End Results.
aLung cancer incidence rate per 100000 person-years. SEER.
Table A2 Lung cancer and mortality rates per 100000 (excluding lung cancer) by age and sex (Whites only) (National Center for Health Statistics, 2003)
Men Women
Age (years) Incidence Mortality Incidence Mortality
20–24 0.26 129.10 0.36 46.70
25–29 0.51 120.00 0.62 50.00
30–34 0.99 136.40 1.26 64.60
35–39 3.40 185.30 4.16 99.80
40–44 10.78 275.10 11.03 153.20
45–49 25.49 400.70 23.19 218.80
50–54 56.60 560.00 45.51 313.40
55–59 116.58 786.90 93.93 479.10
60–64 221.18 1210.20 164.90 762.90
65–69 346.77 1855.10 246.85 1197.00
70–74 478.10 2947.40 318.69 1968.30
75–79 564.36 4836.40 344.67 3306.10
80–84 532.36 7980.70 308.28 5761.20
485 498.44 15559.40 266.72 14016.20
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